neutrophil cytoplasmic antibody (ANCA) in body fluid
Jump to navigation
Jump to search
Introduction
Also see cANCA, pANCA & see ARUP consult[7]
Indications
Reference interval
- negative
- < 1:20
Clinical significance
- useful test in patient's with Wegener's granulomatosis, related vasculitides & glomerular diseases
- perinuclear (pANCA) & cytoplasmic patterns (cANCA) are 2 patterns recognized by indirect immunofluorescence
- the cytoplasmic pattern (cANCA) is directed against myeloblastin (serine proteinase-3)
- the perinuclear pattern (pANCA) may be directed against myeloperoxidase or leukocyte elastase.
Associated factors:[6]
- genetic predisposition
- environmental triggers (silica exposure)
- infections (tuberculosis, HIV, hepatitis C, parvovirus B19, mycosis)
- neoplasia (lympohoma, myelodysplasia, monoclonal gammopathy)
- drugs (propythyouracil, cocaine, minocycline)
Methods
- indirect immunofluorescence on fixed neutrophilic granules
- distinctive patterns perinuclear (an artifact of fixation) & cytoplasmic may be observed
- solid phase EIA's are in development
Specimen
store at -20 C
More general terms
More specific terms
- cANCA in body fluid; anti-myeloblastin in body fluid; anti-serine protease 3 in body fluid
- neutrophil cytoplasmic antibody (ANCA) in CSF
Additional terms
References
- ↑ Clinical Guide to Laboratory Tests, NW Tietz (ed) 3rd ed, WB Saunders, Philadelphia 1995
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 782, 847
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1913
- ↑ Kaiser Permanente Northern Calfornia Regional Laboratory
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, 16. American College of Physicians, Philadelphia 1998, 2012
- ↑ 6.0 6.1 Bosch X et al, Antineutrophil cytoplasmic antibodies. Lancet 2006, 368:404 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16876669
- ↑ 7.0 7.1 ARUP Consult: Systemic Vasculitis https://arupconsult.com/content/vasculitis